Escherichia coli Infections - Pipeline Review, H1 2016

Published: May, 2016 | Pages: 168 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Escherichia coli Infections - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Escherichia coli Infections - Pipeline Review, H1 2016', provides an overview of the Escherichia coli Infections pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Escherichia coli Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Escherichia coli Infections and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Escherichia coli Infections
- The report reviews pipeline therapeutics for Escherichia coli Infections by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Escherichia coli Infections therapeutics and enlists all their major and minor projects
- The report assesses Escherichia coli Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Escherichia coli Infections

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Escherichia coli Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Escherichia coli Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Escherichia coli Infections Overview 10
Therapeutics Development 11
Pipeline Products for Escherichia coli Infections - Overview 11
Pipeline Products for Escherichia coli Infections - Comparative Analysis 12
Escherichia coli Infections - Therapeutics under Development by Companies 13
Escherichia coli Infections - Therapeutics under Investigation by Universities/Institutes 15
Escherichia coli Infections - Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Escherichia coli Infections - Products under Development by Companies 18
Escherichia coli Infections - Products under Investigation by Universities/Institutes 21
Escherichia coli Infections - Companies Involved in Therapeutics Development 22
Adenium Biotech ApS 22
Arsanis Biosciences GmbH 23
AstraZeneca Plc 24
AvidBiotics Corp. 25
Bioorganic Research and Services S.A. 26
Cellceutix Corporation 27
Cytovation AS 28
Debiopharm International SA 29
Emergent BioSolutions Inc. 30
F. Hoffmann-La Roche Ltd. 31
GangaGen Inc. 32
GlaxoSmithKline Plc 33
Johnson & Johnson 34
Melinta Therapeutics, Inc 35
Microbiotix, Inc. 36
MicuRx Pharmaceuticals, Inc. 37
Nabriva Therapeutics AG 38
Navigen Pharmaceuticals, Inc. 39
Nosopharm SAS 40
Novabiotics Limited 41
Omnia Molecular Ltd. 42
Pherecydes Pharma SA 43
Phico Therapeutics Limited 44
Procarta Biosystems Limited 45
Sealife PHARMA GMBH 46
Sequoia Sciences, Inc. 47
Soligenix, Inc. 48
Syntiron LLC 49
Tetraphase Pharmaceuticals Inc. 50
Varinel, Inc. 51
Visterra, Inc. 52
Escherichia coli Infections - Therapeutics Assessment 53
Assessment by Monotherapy Products 53
Assessment by Target 54
Assessment by Mechanism of Action 56
Assessment by Route of Administration 58
Assessment by Molecule Type 60
Drug Profiles 62
A-3APO - Drug Profile 62
AA-139 - Drug Profile 64
ASN-4 - Drug Profile 65
AvR2-V10 - Drug Profile 66
BC-7634 - Drug Profile 68
BC-9074 - Drug Profile 69
BC-9529 - Drug Profile 70
BC-9563 - Drug Profile 71
BIZ-20131 - Drug Profile 72
BIZ-20132 - Drug Profile 73
BIZ-20133 - Drug Profile 74
BNT-006 - Drug Profile 75
CC-1807 - Drug Profile 76
CyPep-1 - Drug Profile 77
Debio-1454 - Drug Profile 78
Drugs for Bacterial Infections - Drug Profile 79
dusquetide - Drug Profile 80
EcoXyn-4V - Drug Profile 82
Escherichia coli (whole cell) vaccine - Drug Profile 83
Escherichia coli vaccine - Drug Profile 84
Escherichia coli vaccine - Drug Profile 85
ETEC vaccine - Drug Profile 86
EV-035 - Drug Profile 87
GN snare - Drug Profile 89
GN-4474 - Drug Profile 90
INX-201 - Drug Profile 91
JNJ-63871860 - Drug Profile 92
LTA-001 - Drug Profile 94
MBX-2319 - Drug Profile 95
MDN-0057 - Drug Profile 96
MRX-V - Drug Profile 98
NBTI-5463 - Drug Profile 99
NOSO-95179 - Drug Profile 100
NP-432 - Drug Profile 101
Onc-72 - Drug Profile 102
P-100031 - Drug Profile 103
Peptides for Infectious Diseases - Drug Profile 104
PMX-100 - Drug Profile 105
PMX-1091 - Drug Profile 106
PMX-1142 - Drug Profile 107
PMX-1241 - Drug Profile 108
PMX-1278 - Drug Profile 109
PMX-1363 - Drug Profile 110
PMX-1405 - Drug Profile 111
PMX-223 - Drug Profile 112
PMX-229 - Drug Profile 113
PMX-247 - Drug Profile 114
PMX-633 - Drug Profile 115
PMX-668 - Drug Profile 116
PMX-693 - Drug Profile 117
PMX-843 - Drug Profile 118
PP-0121 - Drug Profile 119
Proteins for Infectious Diseases - Drug Profile 121
PT-4 - Drug Profile 122
Recombinant Protein for Escherichia Coli Infections - Drug Profile 123
RX-05 - Drug Profile 124
RXP-873 - Drug Profile 125
SE-1 - Drug Profile 126
Shigetec - Drug Profile 127
SLP-0901 - Drug Profile 128
SLP-0905 - Drug Profile 129
Small Molecule for Gram-Negative Nosocomial Infections - Drug Profile 130
Small Molecule for Malaria and Bacterial Infections - Drug Profile 131
Small Molecule to Activate IL-10 for Bacterial Infections and Crohn's Disease - Drug Profile 132
Small Molecules for Bacterial Infections - Drug Profile 133
Small Molecules for Escherichia Coli Infections - Drug Profile 134
Small Molecules for Escherichia coli Infections - Drug Profile 135
Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Drug Profile 136
Small Molecules to Inhibit 16S rRNA, Topoisomerases II and IV for Bacterial Infections - Drug Profile 137
Small Molecules to Inhibit Aminoacyl-tRNA Synthetases for Bacterial Infections - Drug Profile 138
Small Molecules to Inhibit RecA for Bacterial Infections - Drug Profile 139
Synthetic Peptide for Gram-Negative Bacterial Infections - Drug Profile 140
Synthetic Peptide for Oncology and Infectious Disease - Drug Profile 141
Synthetic Peptide to Antagonize TLR-4 for Oncology, Immunology and Infectious Disease - Drug Profile 142
Synthetic Peptides for Escherichia Coli Infections - Drug Profile 143
TP-6076 - Drug Profile 144
VAR-10100 - Drug Profile 145
VIS-GMN - Drug Profile 146
Escherichia coli Infections - Recent Pipeline Updates 147
Escherichia coli Infections - Dormant Projects 157
Escherichia coli Infections - Discontinued Products 160
Escherichia coli Infections - Product Development Milestones 161
Featured News & Press Releases 161
Appendix 162
Methodology 162
Coverage 162
Secondary Research 162
Primary Research 162
Expert Panel Validation 162
Contact Us 162
Disclaimer 163

List of Tables

Number of Products under Development for Escherichia coli Infections, H1 2016 16
Number of Products under Development for Escherichia coli Infections - Comparative Analysis, H1 2016 17
Number of Products under Development by Companies, H1 2016 18
Number of Products under Development by Companies, H1 2016 (Contd..1) 19
Number of Products under Investigation by Universities/Institutes, H1 2016 20
Comparative Analysis by Clinical Stage Development, H1 2016 21
Comparative Analysis by Early Stage Development, H1 2016 22
Products under Development by Companies, H1 2016 23
Products under Development by Companies, H1 2016 (Contd..1) 24
Products under Development by Companies, H1 2016 (Contd..2) 25
Products under Investigation by Universities/Institutes, H1 2016 26
Escherichia coli Infections - Pipeline by Adenium Biotech ApS, H1 2016 27
Escherichia coli Infections - Pipeline by Arsanis Biosciences GmbH, H1 2016 28
Escherichia coli Infections - Pipeline by AstraZeneca Plc, H1 2016 29
Escherichia coli Infections - Pipeline by AvidBiotics Corp., H1 2016 30
Escherichia coli Infections - Pipeline by Bioorganic Research and Services S.A., H1 2016 31
Escherichia coli Infections - Pipeline by Cellceutix Corporation, H1 2016 32
Escherichia coli Infections - Pipeline by Cytovation AS, H1 2016 33
Escherichia coli Infections - Pipeline by Debiopharm International SA , H1 2016 34
Escherichia coli Infections - Pipeline by Emergent BioSolutions Inc., H1 2016 35
Escherichia coli Infections - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 36
Escherichia coli Infections - Pipeline by GangaGen Inc., H1 2016 37
Escherichia coli Infections - Pipeline by GlaxoSmithKline Plc, H1 2016 38
Escherichia coli Infections - Pipeline by Johnson & Johnson, H1 2016 39
Escherichia coli Infections - Pipeline by Melinta Therapeutics, Inc, H1 2016 40
Escherichia coli Infections - Pipeline by Microbiotix, Inc., H1 2016 41
Escherichia coli Infections - Pipeline by MicuRx Pharmaceuticals, Inc., H1 2016 42
Escherichia coli Infections - Pipeline by Nabriva Therapeutics AG, H1 2016 43
Escherichia coli Infections - Pipeline by Navigen Pharmaceuticals, Inc., H1 2016 44
Escherichia coli Infections - Pipeline by Nosopharm SAS, H1 2016 45
Escherichia coli Infections - Pipeline by Novabiotics Limited, H1 2016 46
Escherichia coli Infections - Pipeline by Omnia Molecular Ltd., H1 2016 47
Escherichia coli Infections - Pipeline by Pherecydes Pharma SA, H1 2016 48
Escherichia coli Infections - Pipeline by Phico Therapeutics Limited, H1 2016 49
Escherichia coli Infections - Pipeline by Procarta Biosystems Limited, H1 2016 50
Escherichia coli Infections - Pipeline by Sealife PHARMA GMBH, H1 2016 51
Escherichia coli Infections - Pipeline by Sequoia Sciences, Inc., H1 2016 52
Escherichia coli Infections - Pipeline by Soligenix, Inc., H1 2016 53
Escherichia coli Infections - Pipeline by Syntiron LLC, H1 2016 54
Escherichia coli Infections - Pipeline by Tetraphase Pharmaceuticals Inc., H1 2016 55
Escherichia coli Infections - Pipeline by Varinel, Inc., H1 2016 56
Escherichia coli Infections - Pipeline by Visterra, Inc., H1 2016 57
Assessment by Monotherapy Products, H1 2016 58
Number of Products by Stage and Target, H1 2016 60
Number of Products by Stage and Mechanism of Action, H1 2016 62
Number of Products by Stage and Route of Administration, H1 2016 64
Number of Products by Stage and Molecule Type, H1 2016 66
Escherichia coli Infections Therapeutics - Recent Pipeline Updates, H1 2016 152
Escherichia coli Infections - Dormant Projects, H1 2016 162
Escherichia coli Infections - Dormant Projects (Contd..1), H1 2016 163
Escherichia coli Infections - Dormant Projects (Contd..2), H1 2016 164
Escherichia coli Infections - Discontinued Products, H1 2016 165